--- title: "Balanced Risk/Reward at uniQure: Early Promise for AMT-191 Offset by Regulatory and Competitive Uncertainty Around AMT-130" type: "News" locale: "en" url: "https://longbridge.com/en/news/275159699.md" description: "William Blair analyst Sami Corwin maintains a Hold rating on uniQure (QURE) stock, citing a balanced risk/reward scenario. Positive data for AMT-191 shows strong enzyme activity, but competition from Sangamo's advanced Fabry gene therapy tempers optimism. Uncertainty surrounds AMT-130's regulatory path, with no clear timeline for a BLA filing. Corwin's analysis reflects cautious optimism, leading to a neutral stance on the stock. TipRanks also supports a Hold rating with a $25.00 price target." datetime: "2026-02-06T17:25:23.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/275159699.md) - [en](https://longbridge.com/en/news/275159699.md) - [zh-HK](https://longbridge.com/zh-HK/news/275159699.md) --- > Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/275159699.md) | [繁體中文](https://longbridge.com/zh-HK/news/275159699.md) # Balanced Risk/Reward at uniQure: Early Promise for AMT-191 Offset by Regulatory and Competitive Uncertainty Around AMT-130 William Blair analyst Sami Corwin has reiterated their neutral stance on QURE stock, giving a Hold rating on January 28. ### Claim 50% Off TipRanks Premium - Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions - Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential Sami Corwin has given his Hold rating due to a combination of factors related to both opportunity and uncertainty in uniQure’s pipeline. The new Fabry disease data for AMT-191 are directionally positive, showing strong and durable enzyme activity as well as a meaningful proportion of patients able to discontinue enzyme replacement therapy, which supports the potential of this asset. At the same time, a competing Fabry gene therapy from Sangamo is further along, with a rolling BLA already underway and supported by an endpoint (eGFR) that uniQure has not yet reported for AMT-191, tempering the near-term competitive positioning. Corwin also emphasizes that investor attention is centered on the future of AMT-130, where regulatory clarity will be a major driver of the stock. While upcoming interactions with regulators could be a catalyst, there is currently no defined timeline or clear path toward a BLA or similar filing for AMT-130, leaving a high degree of strategic and regulatory uncertainty. This mix of encouraging but early-stage data for AMT-191 and an unclear development trajectory for AMT-130 leads Corwin to view the risk/reward as balanced rather than compellingly skewed to the upside, supporting the decision to maintain a Hold (Market Perform) rating on uniQure shares. According to TipRanks, Corwin is a 5-star analyst with an average return of 13.0% and a 49.62% success rate. Corwin covers the Healthcare sector, focusing on stocks such as Solid Biosciences, Applied Therapeutics, and Cabaletta Bio. In another report released on January 28, TipRanks – OpenAI also reiterated a Hold rating on the stock with a $25.00 price target. ### Related Stocks - [VanEck Biotech ETF (BBH.US)](https://longbridge.com/en/quote/BBH.US.md) - [First Trust NYSE Arca Biotech ETF (FBT.US)](https://longbridge.com/en/quote/FBT.US.md) - [Invesco Nasdaq Biotechnology ETF (IBBQ.US)](https://longbridge.com/en/quote/IBBQ.US.md) - [ALPS Medical Breakthroughs ETF (SBIO.US)](https://longbridge.com/en/quote/SBIO.US.md) - [Sangamo Therapeutics, Inc. (SGMO.US)](https://longbridge.com/en/quote/SGMO.US.md) - [Direxion Daily S&P Biotech Bear 3X ETF (LABD.US)](https://longbridge.com/en/quote/LABD.US.md) - [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/en/quote/PBE.US.md) - [ProShares Ultra Nasdaq Biotechnology (BIB.US)](https://longbridge.com/en/quote/BIB.US.md) ## Related News & Research - [These Analysts Cut Their Forecasts On uniQure Following Q4 Results](https://longbridge.com/en/news/277641219.md) - [FDA official says UniQure fell short on Huntington's trial, defends new study request](https://longbridge.com/en/news/277874344.md) - [Regenxbio Q4 R&D expenses rise 18.3% to USD 59.6 million](https://longbridge.com/en/news/277931863.md) - [Ocugen 10-K: Revenue $4.4M, Net Loss $67.8M](https://longbridge.com/en/news/277812097.md) - [Opus Genetics Announces Initial Clinical Data from Phase 1/2 OPGx-BEST1 Gene Therapy Study at the Macula Society Annual Meeting | IRD Stock News](https://longbridge.com/en/news/277220357.md)